ChemoMetec AS (OCSE:CHEMM) Research & Development: kr0.0 Mil (TTM As of Dec. 2025)


OCSE:CHEMM ChemoMetec AS OCSE:CHEMM
99 GF Score
Price kr369.20
GF Value kr523.33
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is ChemoMetec AS Research & Development?

ChemoMetec AS OCSE:CHEMM +0.76% 99 Research & Development is kr0.0 Mil as of Dec. 2025. GuruFocus rates OCSE:CHEMM with a GF Score™ of 99/100 and a GF Value™ of kr523.33 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. ChemoMetec AS's Research & Development for the six months ended in Dec. 2025 was kr0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was kr0.0 Mil.

ChemoMetec AS  (OCSE:CHEMM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

ChemoMetec AS Research & Development Related Terms

ChemoMetec AS Research & Development Historical Data

* Premium members only.

The historical data trend for ChemoMetec AS's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ChemoMetec AS Research & Development Chart

ChemoMetec AS Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ChemoMetec AS Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OCSE:CHEMM
99GF Score
ChemoMetec AS OCSE:CHEMM
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ChemoMetec AS Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr0.0 Mil mean?
ChemoMetec AS (OCSE:CHEMM) has a Research & Development of kr0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on ChemoMetec AS and its competitors.
Is ChemoMetec AS's Research & Development too high?
ChemoMetec AS's current Research & Development is kr0.0 Mil. Overall, ChemoMetec AS has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's Research & Development compare to ABT and SYK?
ChemoMetec AS's Research & Development of kr0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on ChemoMetec AS and its competitors. ChemoMetec AS's current Research & Development is kr0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr523.33, compared to a current price of kr369.20 — trading 29.5% below its estimated fair value. The current Research & Development is kr0.0 Mil. ChemoMetec AS's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current Research & Development is kr0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?

Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued. The current stock price of kr369.20 is trading 29.5% below its estimated GF Value™ of kr523.33. GuruFocus considers ChemoMetec AS to be Modestly Undervalued.

Key valuation signals for OCSE:CHEMM:

  • Research & Development: kr0.0 Mil
  • GF Value™: kr523.33 vs. price of kr369.20 (29.5% below fair value)
  • GF Score™: 99/100 with 2 warning signs

No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ChemoMetec AS Business Description

Other Exchanges CHEMMc:UK0DZ0:UKCHY:Germany
Address Gydevang 43, Allerod, DNK, 3450
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
99GF Score

Get the complete analysis for OCSE:CHEMM

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr369.20
Price
kr523.33
GF Value